Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2013 Jun 13;121(24):4847-53. doi: 10.1182/blood-2013-02-474833. Epub 2013 May 6.

Recent progress toward epigenetic therapies: the example of mixed lineage leukemia.

Author information

1
Center for Cancer and Blood Disorders, Children's Hospital Colorado, and Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO, USA.

Abstract

The importance of epigenetic gene regulatory mechanisms in normal and cancer development is increasingly evident. Genome-wide analyses have revealed the mutation, deletion, and dysregulated expression of chromatin-modifying enzymes in a number of cancers, including hematologic malignancies. Genome-wide studies of DNA methylation and histone modifications are beginning to reveal the landscape of cancer-specific chromatin patterns. In parallel, recent genetic loss-of-function studies in murine models are demonstrating functional involvement of chromatin-modifying enzymes in malignant cell proliferation and self-renewal. Paradoxically, the same chromatin modifiers can, depending on cancer type, be either hyperactive or inactivated. Increasingly, cross talk between epigenetic pathways is being identified. Leukemias carrying MLL rearrangements are quintessential cancers driven by dysregulated epigenetic mechanisms in which fusion proteins containing N-terminal sequences of MLL require few or perhaps no additional mutations to cause human leukemia. Here, we review how recent progress in the field of epigenetics opens potential mechanism-based therapeutic avenues.

PMID:
23649466
PMCID:
PMC3682337
DOI:
10.1182/blood-2013-02-474833
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center